Polaris Group Acquires Genovior Biotech for ~$70M
Shots:
- The Polaris Group has extended its acquisition of Genovior Biotech to acquire 100% of Genovior's shares allowing Polaris to expand its product pipeline beyond cancer metabolism therapies to include peptide drugs such as Semaglutide-related products
- As per the terms of the agreement, Polaris acquired Genovior’s share for an aggregate of ~$70M thereby gaining access to its peptide product pipeline & its workforce in Taiwan
- Earlier in Nov 2023, Polaris submitted a BLA rolling submission to the US FDA for its anti-cancer drug, ADI-PEG 20 for the treatment of malignant pleural mesothelioma. Moreover, Polaris also has 3 ongoing P-III trials in GBM, LMS & HCC
Ref: Polaris | Image: Polaris
Related News:- Polaris Group Initiates P-IIa Clinical Study for NASH, Dosing First Patient with ADI-PEG 20
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
